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Abstract
Background: In a proportion of patients with HIV-associated tuberculosis who develop paradoxical immune
reconstitution inflammatory syndrome (IRIS), the clinical course of IRIS is prolonged necessitating substantial
health care utilization for diagnostic and therapeutic interventions. Prolonged TB-IRIS has not been prospectively
studied to date. We aimed to determine the proportion of patients with prolonged TB-IRIS, as well as the clinical
characteristics and risk factors for prolonged TB-IRIS.
Methods: We pooled data from two prospective observational studies and a randomized controlled trial conducted in
Cape Town, South Africa, that enrolled patients with paradoxical TB-IRIS. We used the same diagnostic approach
and clinical case definitions for TB-IRIS in the 3 studies. Prolonged TB-IRIS was defined as TB-IRIS symptoms
lasting > 90 days. Risk factors for prolonged TB-IRIS were analysed using Wilcoxon rank sum test, Fisher’s exact
test, multivariate logistic regression and Cox proportional hazards models.
Results: Two-hundred and sixteen patients with TB-IRIS were included. The median duration of TB-IRIS symptoms
was 71.0 days (IQR 41.0–113.2). In 73/181 patients (40.3 %) with adequate follow-up data, IRIS duration was > 90 days.
Six patients (3.3 %), mainly with lymph node involvement, had IRIS duration > 1 year. In univariate logistic regression
analysis the following were significantly associated with IRIS duration > 90 days: lymph node involvement at initial TB
diagnosis, drug-resistant TB, lymph node TB-IRIS, and not being hospitalised at time of TB-IRIS diagnosis. In
our multivariate logistic regression model lymph node TB-IRIS (aOR 2.27, 95 % CI 1.13–4.59) and not being
hospitalised at time of TB-IRIS diagnosis (aOR for being hospitalised 0.5, 95 % CI 0.25-0.99) remained significantly
associated with prolonged TB-IRIS, and drug-resistant TB was of borderline significance (aOR 3.26, 95 % CI 0.97–12.99).
The association of not being hospitalised with longer duration of IRIS might be related to 1 of the 3 cohorts in
which all patients were hospitalised at ART initiation with close inpatient follow-up. This could have resulted in
diagnosis of milder cases and earlier IRIS treatment potentially resulting in shorter TB-IRIS duration in these
hospitalised patients.
Conclusions: Around 40 % of patients with TB-IRIS have symptoms for more than 90 days. Involvement of lymph
nodes at time of TB-IRIS is an independent risk factor for prolonged TB-IRIS. Future studies should address whether
more prompt anti-inflammatory treatment of lymph node TB-IRIS reduces the risk of prolonged TB-IRIS.
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Background
Paradoxical tuberculosis-associated immune reconstitu-
tion inflammatory syndrome (TB-IRIS) is an immuno-
pathological reaction occurring in 4–54 % patients who
start antiretroviral therapy (ART) while on treatment for
tuberculosis (TB) [1–3]. Mortality directly attributed to
paradoxical TB-IRIS is not frequent [4]. However, TB-
IRIS causes substantial morbidity, necessitating hospital-
isation and health care utilisation for diagnostic and
therapeutic procedures [5, 6], particularly when TB-IRIS
has a protracted clinical course. The median duration of
TB-IRIS symptoms reported from several observational
studies and clinical trials has been 1–3 months [5–11].
However, the condition may persist longer, more than 1
year in certain cases [2, 5, 9–12]. Prolonged corticoster-
oid therapy in such patients may be associated with
significant complications.
The risk factors and clinical features of patients who
develop a prolonged course of TB-IRIS have not been
systematically studied. We conducted this study to de-
termine the proportion of TB-IRIS patients that experi-
enced a prolonged clinical course (defined as symptoms
lasting > 90 days), as well as their clinical characteristics,
outcomes, and risk factors.
Methods
Study design
We pooled data from three prospective studies of TB-
IRIS that our group conducted in Cape Town, South
Africa between 2005 and 2010 [13–15]. Data from eli-
gible TB-IRIS cases assessed and followed up in these
studies were included in this combined post hoc analysis.
One of these studies was a randomized controlled trial
(RCT) and the other two were prospective observational
cohort studies. The RCT (n = 110) was conducted at GF
Jooste Hospital with enrollment between June 2005 and
December 2007. This was a secondary-level university-
affiliated hospital serving communities with high HIV/
TB co-infection rates. Patients were usually started on
TB treatment and ART in primary care clinics and re-
ferred to the hospital with suspected TB-IRIS. The treat-
ment intervention was a 4-week course of prednisone
(1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day
for a further 2 weeks). The trial was placebo-controlled
with 1:1 randomisation. Trial design allowed patients
who deteriorated or relapsed after stopping study drug
to be commenced on open-label prednisone at clinician
discretion. The trial duration was 12 weeks, but if pa-
tients still had TB-IRIS symptoms at 12 weeks follow-up
was continued until TB-IRIS resolved [14].
The first observational cohort study (Cohort 1) was
also conducted at GF Jooste Hospital at the same time
as the RCT [13]. Between February 2005 and July 2006,
61 patients with TB-IRIS who were seen prior to the
RCT or were ineligible for the RCT (for example be-
cause of neurological TB-IRIS) were enrolled. These pa-
tients were followed as outpatients until resolution of
TB-IRIS symptoms. The second observational cohort
study (Cohort 2) was conducted at Brooklyn Chest TB
Hospital, also in Cape Town, with recruitment between
May 2009 and November 2010 [15]. This was a study of
ART-naïve patients who required hospitalisation for the
treatment for HIV-associated TB and who started ART
while admitted to this TB hospital and were followed for
at least 12 weeks. Forty-seven TB-IRIS cases were diag-
nosed in this study and patients were followed for longer
than 12 weeks if TB-IRIS was ongoing.
TB was diagnosed microbiologically (smear or culture)
or using World Health Organization (WHO) guidelines
for the diagnosis of smear-negative pulmonary and
extrapulmonary TB [16]. Patients were treated according
to national guidelines for TB and HIV. During the study
periods TB cases received 6 months of therapy (rifampicin,
isoniazid, pyrazinamide, and ethambutol for 2 months,
followed by rifampin and isoniazid for 4 months). The
retreatment regimen included the addition of streptomycin
for the first 2 months of an 8-month regimen. Routine TB
drug susceptibility testing (DST) was not performed for
new TB cases. Patients receiving retreatment and patients
not responding to TB treatment may have had DST per-
formed. DST was only performed for rifampin, isoniazid,
and ethambutol using culture-based techniques as previ-
ously described [13]. When multi- drug resistant TB was
diagnosed a standard multi-drug resistant TB regimen was
prescribed. First-line ART in South Africa at the time of
these studies was stavudine, lamivudine, and either nevira-
pine or efavirenz. Efavirenz was preferred for patients
receiving rifampicin-based TB treatment. Patients with a
CD4 cell count <200 cells/μl and/or World Health
Organization stage 4 disease were eligible to commence
ART. In April 2010, the guidelines changed: tenofovir re-
placed stavudine, and TB patients were eligible for ART
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with a CD4 count < 350 cells/μl. Laboratory tests were
performed by the National Health Laboratory Services
(NHLS).
The same approach to diagnosing TB-IRIS was used
across the studies. In those with suspected TB-IRIS, our
clinical assessment sought to exclude differential diagno-
ses based on clinical presentation (for example, in those
with respiratory symptoms, bacterial and pneumocystis
pneumonia were investigated). In TB-IRIS patients, spu-
tum (or extra-pulmonary) samples were sent when they
could be obtained to exclude rifampicin resistant TB.
Study definitions
All patients included in this analysis fulfilled the Inter-
national Network for the Study of HIV-associated IRIS
(INSHI) consensus case definition for paradoxical TB-
IRIS [2] with one exception: not all patients with drug
resistant TB were excluded. We have previously de-
scribed an overlap of TB-IRIS and rifampicin resistant
TB [13] and for this reason when a patient with drug re-
sistant TB was also considered to have TB-IRIS they
were not excluded from the analyses as we wished to de-
termine if underlying drug resistant TB was a risk factor
for prolonged TB-IRIS.
Pulmonary TB-IRIS was defined as new, recurrent or
worsening respiratory symptoms and/or a worsening
chest radiograph pulmonary infiltrate. Lymph node TB-
IRIS was defined by enlarging peripheral lymph nodes
on clinical examination, or enlarging thoracic nodes on
chest radiograph or enlarging abdominal nodes on ultra-
sound or CT scan. Abdominal TB-IRIS was defined by
abdominal symptoms (eg. abdominal pain or vomiting)
attributed to TB-IRIS rather than an alternative cause
(eg. adverse drug reaction), clinical hepatomegaly, or fea-
tures of abdominal TB on ultrasound (eg. lymphadenop-
athy). Multi-organ TB-IRIS was defined by the presence
of TB-IRIS symptoms, clinical signs or radiological/
ultrasound abnormalities that involved more than 1
organ system (eg. pulmonary and nodal). These defini-
tions relate to any features present at TB-IRIS presenta-
tion or that developed at any time during the course of
the TB-IRIS episode. Only patients with abdominal
symptoms had an abdominal ultrasound performed at
time of TB-IRIS.
Prolonged paradoxical TB-IRIS was defined as TB-
IRIS symptoms lasting more than 90 days. This was
chosen because previous studies have reported a median
duration of TB-IRIS of 1–3 months [5–11]. IRIS symp-
tom onset date was as reported by the patient. IRIS end
date was recorded as date of resolution of all symptoms
attributed to TB-IRIS. If a patient was asymptomatic,
but had only a persistent pulmonary infiltrate, tachycardia
or hepatomegaly this did not constitute ongoing IRIS. In
patients manifesting with lymph node enlargement due to
TB-IRIS, IRIS resolution date was recorded when patients
complained of no symptoms related to lymph nodes,
and nodes had reduced in size by more than half of
initial size or when node(s) were less than 2 cm in
maximal diameter.
Data collection
Clinical data regarding TB presentation and diagnosis,
HIV history, TB-IRIS symptoms, corticosteroid treat-
ment and duration, as well as laboratory results were ex-
tracted from the study databases using a standard data
extraction form. When necessary the source notes were
reviewed to extract other relevant data.
Statistical analyses
Data analysis was performed using GraphPad Prism (La
Jolla, CA) and R 3.0. Median and interquartile range
(IQR) are presented for continuous variables and fre-
quency and percentage for categorical variables. P-values
were estimated from Fisher’s exact test (for categorical
variables) and the Wilcoxon rank sum test (for continu-
ous variables). P-values ≤ 0.05 were taken to be statisti-
cally significant.
The analyses were performed on a combined database
from the 3 studies (Fig. 1). Duration of TB-IRIS symp-
toms and clinical features of those patients with pro-
longed TB-IRIS (>90 days and > 1 year) were described.
Factors associated with prolonged TB-IRIS were ana-
lysed in univariate analysis, followed by multivariate
logistic regression analysis. The multivariate logistic re-
gression model included all variables with p-value < 0.1
by univariate analysis and certain pre-specified adjust-
ment variables (eg. gender). A Cox proportions hazards
model was developed in order to assess variables inde-
pendently associated with time to resolution of TB-IRIS.
Proportional hazards assumptions were verified using
scaled Schoenfeld residuals. A competing risk analysis
accounting for mortality was also performed.
For the analyses of factors associated with prolonged
TB-IRIS (>90 days) patients who were lost to follow up
or died prior to 90 days and before IRIS resolution were
excluded from the univariate analyses and multivariate
logistic regression models. They were included in the
Cox proportional hazards and competing risks models
and censored at death or loss to follow-up if these oc-
curred before IRIS resolution.
Results
Two-hundred and sixteen patients were diagnosed with
paradoxical TB-IRIS across the three studies. One hun-
dred eighty one patients were included in the initial ana-
lyses that compared patients with IRIS duration ≤ 90 days
versus > 90 days. Reasons for exclusion from these ana-
lyses were mainly because patients were lost to follow-up
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or died before 90 days and before IRIS resolution (Fig. 1).
In the Cox proportional hazards and competing risks
models 212 patients were included, as these analyses
allowed inclusion of patients who did not have a known
IRIS resolution date (in four patients the TB-IRIS start
date was not known and they were excluded). The charac-
teristics of the 212 patients are summarized in Table 1.
Among the 181 participants included in the initial ana-
lyses, 116 (64.1 %) were female and their median age was
31 years (IQR 27–36). The median CD4 count prior to
ART was 53 cells/μl (IQR 29–94) and at first TB-IRIS as-
sessment was 117 cells/μl (IQR 71–218). The TB diagnosis
was made by culture of Mycobacterium tuberculosis in 97
(53.6 %), positive smear for acid-fast bacilli in 41 (22.7 %)
and clinical/radiological diagnosis in 43 (23.8 %). One-
hundred and fifteen patients (63.5 %) had extra-pulmonary
involvement at TB diagnosis. The median duration from
starting TB treatment to ART was 56.0 days (IQR 31.0–
81.3). Median duration from ART to TB-IRIS symptom
onset was 13.5 days (IQR 7.0–19.3 days). The most fre-
quent organ systems involved by TB-IRIS were: abdominal
(n = 140, 77.3 %), pulmonary (n = 72, 39.8 %) and lymph
nodes (n = 71, 39.2 %). In 150 patients (82.9 %) there was
multi-system involvement. At the time of TB-IRIS
Fig. 1 Inclusion and exclusion of patients in the prolonged TB-IRIS analyses. The total study population included 216 TB-IRIS patients from three
prior studies (one randomised controlled trial and two prospective observational cohort studies). The initial analyses comparing those who experienced
a prolonged course of TB-IRIS symptoms (defined as lasting more than 90 days) to those that did not experience a prolonged course of
TB-IRIS included 181 patients. Reasons for exclusion of 35 patients from these analyses are shown. Abbreviations: ART = antiretroviral therapy,
IRIS = immune reconstitution inflammatory syndrome, RCT = randomised controlled trial, TB = tuberculosis
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diagnosis among the 181 patients, 83 (45.9 %) were hospi-
talised including all 47 patients in Cohort 2 (for five
patients this data was missing).
The median duration of TB-IRIS symptoms was
71.0 days (IQR 41.0–113.2) for those who had a known
TB-IRIS start and resolution date (n = 172, this excluded
all those who died or were lost to follow-up prior to TB-
IRIS resolution even if beyond 90 days). In the 181 pa-
tients, IRIS duration was longer than 90 days in 73
(40.3 %) and 6 (3.3 %) had IRIS duration of over one
year. The distribution of duration is shown in Additional
file 1: Figure S1.
One hundred and eleven of the 181 patients included in
initial analyses (61.3 %) received prednisone treatment for
TB-IRIS for a median 42 days (IQR 28–91). This included
prednisone received as study drug or open-label prednis-
one in the RCT and as TB-IRIS treatment in the observa-
tional cohorts. In the RCT and in clinical practice
standard practice was to start prednisone at a dose of
1.5 mg/kg/day. Outside of the RCT, clinician practice was
to taper prednisone according to symptom response.
Among all 216 patients, 16 patients (7.4 %, 95 % CI 4.5 –
11.8 %) were known to have died a median of 33.5 days
(IQR 28–61.5) after TB-IRIS onset. Fourteen patients died
within 90 days and two patients died after 90 days. TB-IRIS
was considered the main cause of death in five of the 16
deaths. The most frequent other cause of death among the
TB-IRIS cases was sepsis (n = 5).
Characteristics of patients with prolonged TB-IRIS
Among the 73 patients with TB-IRIS lasting > 90 days
the following features were present either at presentation
or at some time during the course of their TB-IRIS:
lymph node involvement in 40/73 (54.8 %), pulmonary
involvement in 23/73 (31.5 %), abdominal involvement
in 59/73 (80.8 %) and pleural, pericardial effusions or
ascites in 18/73 (24.7 %). In 64/73 (87.7 %) there was
multi-system involvement. There were two deaths among
the patients with prolonged TB-IRIS (>90 days). The char-
acteristics, treatment and clinical course of the six patients
who had TB-IRIS symptom duration > 1 year are summa-
rized in Table 2.
Factors associated with prolonged TB-IRIS
Comparisons between those with prolonged IRIS and
those with IRIS duration ≤ 90 days are shown in Table 3
(n = 181). In univariate statistical comparisons the
following variables were significantly associated with
IRIS duration > 90 days: drug-resistant TB, lymph node
involvement at initial TB diagnosis, lymph node TB-IRIS
and not being hospitalised at the time of TB-IRIS
diagnosis. Treatment with corticosteroids was not
associated with prolonged IRIS.
In univariate logistic regression analyses (Table 4;
unadjusted results) the following variables were signifi-
cantly associated with IRIS duration > 90 days: lymph
node involvement at initial TB diagnosis, drug-resistant
TB and lymph node TB-IRIS. Hospitalisation at the time
of TB-IRIS diagnosis was significantly associated with
Table 1 Baseline and TB-IRIS characteristics of the 212 patients
included in Cox proportional hazards model
Variable Median (interquartile range)
or number (%)
Gender (n = 212)
Female 138 (65.1 %)
Male 74 (34.9 %)
Age (years) (n = 212) 31 (27, 36)
WHO stage (n = 212)
3 71 (33.5 %)
4 141 (66.5 %)
CD4 count prior to ART (cells/μl) (n = 199) 52 (28, 92.5)
CD4 count at TB-IRIS (cells/μl) (n = 95) 116 (71, 209.5)
Previous TB (n = 211) 55 (25.9 %)
Drug-resistant TB (n = 212)a 21 (10 %)
Initial TB diagnosis with extra-pulmonary
involvement (n = 212)
134 (63.2 %)
Initial TB diagnosis with lymph node
involvement (n = 212)
50 (23.6 %)
Duration from TB treatment to ART
(days) (n = 211)
56 (31, 83)
Duration from ART to TB-IRIS onset
(days) (n = 211)
14 (7, 21)
Hospitalised at time of TB-IRIS diagnosis
(n = 206)
107 (50.5 %)
TB-IRIS lymph node involvement (n = 212) 80 (37.7 %)
TB-IRIS pulmonary involvement (n = 212) 83 (39.2 %)
TB-IRIS meningitis (n = 209) 10 (4.7 %)
TB-IRIS abdominal involvement (n = 212) 154 (72.6 %)
TB-IRIS multisystem involvement (n = 212) 166 (78.3 %)
Pulse rate (n = 134) 120 (107.3, 132)
C-reactive protein (mg/l) (n = 195) 103 (63, 158.5)
Haemoglobin (g/dl) (n = 136) 9.1 (8, 10.4)
White cell count
(× 109/l) (n = 132)
5.7 (4.1, 8.1)
ALT (IU/l) (n = 180) 34 (22, 51)
Alkaline phosphatase (IU/l) (n = 164) 159 (107, 274.8)
Corticosteroid treatment for TB-IRIS 125 (59.0 %)
Pulse rate and laboratory values refer to the value obtained when the patient
was first assessed with TB-IRIS symptoms, unless otherwise stated. Numbers in
brackets after the variable name refer to the number of patients for whom
that variable was available
Abbreviations: ALT alanine transferase, ART antiretroviral therapy, IRIS immune
reconstitution inflammatory syndrome, TB tuberculosis, WHO World
Health Organisation
aAmong 21 patients with drug resistant TB: four had rifampicin mono-resistance,
three had isoniazid mono-resistance and 14 had resistance to rifampicin
and isoniazid
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The initial TB-IRIS episode involved lymph nodes and resolved on
prednisone then patient re-presented several months later with
new neurological manifestations and multiple rim-enhancing
lesions in the cerebellum. Brain abscess resection tissue cultured
drug-susceptible MTB.
Experienced recurrence of TB-IRIS symptoms on tapering of
steroids and required re-escalation of steroid doses.





98 Supraclavicular nodes and
large cold abscess
Experienced recurrence of TB-IRIS symptoms on tapering of
steroids and required re-escalation of steroid doses.
3 56 65 Extra-pulmonary TB
(miliary)
Nodal 426 0 Cervical and submandibular
nodes
-
4 26 44 Extra-pulmonary TB
(abdominal)
Abdominal 462 168 Axillary and cervical nodes,
abdominal wall cold
abscesses, mastitis
Patient found to have rifampicin mono-resistant MTB (urine
culture sent at diagnosis) at TB-IRIS diagnosis. She was
commenced on prednisone after commencement of
appropriate treatment for rifampicin mono-resistant TB.
Experienced recurrence of TB-IRIS symptoms on tapering of
steroids and required re-escalation of steroid doses.
5 36 39 Extra-pulmonary TB
(nodal and abdominal)
Nodal 1362 308 Multiple suppurating cervical
nodes, psoas abscesses and
abdominal pus collections
Experienced recurrence of TB-IRIS symptoms on tapering of
steroids and required re-escalation of steroid doses.
Patient still had residual left iliac fossa mass on abdominal
imaging at TB-IRIS resolution that was decreasing in size
and was asymptomatic.
6 39 80 Extra-pulmonary TB
(nodal)
Nodal 519 137 Lymph nodes and cold
abscesses
-













TB-IRIS resolving before 90 days as was the variable co-
hort. Hospitalisation and cohort were collinear and
hence not included together in the same multivariate
model. In our multivariate logistic regression model
(Table 4; adjusted results) lymph node enlargement at
time of TB-IRIS demonstrated a statistically significant
association with IRIS duration > 90 days. Hospitalisation
was associated with an IRIS duration ≤ 90 days. Drug-
resistant TB demonstrated a borderline statistically sig-
nificant positive association with prolonged TB-IRIS
(aOR 3.26, 95 % CI 0.97–12.99).
Due to the potential bias around Cohort 2 and hospi-
talisation (as all patients in Cohort 2 were admitted to a
TB hospital from the time of starting ART and thus at
TB-IRIS onset whereas in the other two studies patients
were only admitted to a general hospital for shorter pe-
riods based on severity of illness at the time), a sensitiv-
ity analysis was performed excluding all individuals in
Cohort 2. Both univariate and multivariate regression
models were assessed (Additional file 2: Table S1) and
although, as expected, the number of variables with sta-
tistically significant associations decreased, the direction
Table 3 Factors associated with prolonged course of paradoxical TB-IRIS (defined as TB-IRIS symptoms lasting longer than 90 days)
(n = 181)
TB-IRIS symptoms > 90 days
(n = 73) (40.3 %)
TB-IRIS symptoms≤ 90 days
(n = 108) (59.7 %)
p-value for comparison
Female gender 50 (68.5) 66 (61.1)
Male gender 23 (31.5) 42 (38.9) 0.39
Age (years) 31 (26, 35) 31 (27, 37) 0.32
WHO stage (n = 181)
3 22 (30.1) 40 (37)
4 51 (69.9) 68 (63) 0.42
CD4 count prior to ART (cells/μl) (n = 170) 57.5 (29, 91.2) 52 (29.2, 101) 0.77
CD4 count at TB-IRIS (cells/μl) (n = 89) 117 (71.7, 193.5) 116 (69, 262.5) 0.77
Previous TB (n = 180) 15 (20.6) 30 (28) 0.34
Drug-resistant TB (n = 181)a 10 (13.7) 4 (3.7) 0.02
Initial TB diagnosis with extra-pulmonary features (n = 181) 49 (67.1) 66 (61.1) 0.5
Initial TB diagnosis with lymph node involvement (n = 178) 25 (34.2) 19 (18.1) 0.02
Duration from TB treatment to ART (days)(n = 181) 58 (33, 84) 56 (31, 79.5) 0.8
Duration from ART to TB-IRIS onset (days) (n = 181) 13 (7, 23) 14 (7, 17) 0.51
Hospitalised at time of TB-IRIS diagnosis (n = 176) 25 (34.2) 58 (56.3) 0.01
TB-IRIS lymph node involvement (n = 181) 40 (54.8) 31 (28.7) < 0.0001
TB-IRIS pulmonary involvement (n = 181) 23 (31.5) 49 (45.4) 0.07
TB-IRIS meningitis (n = 181) 1 (1.4) 5 (4.7) 0.42
TB-IRIS abdominal involvement (n = 181) 59 (80.8) 81 (75) 0.37
TB-IRIS multisystem involvement (n = 181) 64 (87.7) 86 (79.6) 0.17
Pulse rate (n = 120) 121 (105, 133) 119 (108, 130) 0.96
C-reactive protein (mg/l) (n = 172) 111 (74, 157.3) 95.5 (46.6, 165.7) 0.14
Haemoglobin (g/dl) (n = 113) 9.0 (8.0, 10.1) 9.1 (8.0, 10.6) 0.62
White cell count (×109/l) (n = 109) 5.9 (4.2, 7.2) 6.0 (4.4, 8.6) 0.33
ALT (IU/l) (n = 157) 40 (25, 60) 35 (22, 48) 0.13
Alkaline phosphatase (IU/l) (n = 147) 164 (114, 261) 164 (95, 278) 0.46
Corticosteroid treatment for TB-IRIS 48 (65.8 %) 63 (58.3 %) 0.35
Medians (interquartile range) or number (%) are shown. Categorical variables were compared using Fisher’s exact test and continuous variables using Wilcoxon
rank sum test. Pulse rate and laboratory values refer to the value obtained when the patient was first assessed with TB-IRIS symptoms, unless otherwise stated.
Numbers in brackets after the variable name refer to the number of patients for whom that variable was available
Abbreviations: ALT alanine transferase, ART antiretroviral therapy, IRIS immune reconstitution inflammatory syndrome, TB tuberculosis, WHO World
Health Organisation
aAmong 14 patients with drug resistant TB: four had rifampicin mono-resistance, two had isoniazid mono-resistance and eight had resistance to rifampicin
and isoniazid
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and size of the effects remained largely the same. How-
ever, hospitalisation was no longer associated with pro-
longed TB-IRIS (aOR 1.16, 95 % CI 0.53–2.57, p = 0.71).
The Cox proportional hazards model (Table 5) in-
cluded 212 patients for whom the TB-IRIS start date
was known and a multivariate model was run based on
predictors of interest as indicated by previous analyses
and pre-specified variables. Predictors included were:
lymph node involvement at initial TB diagnosis, TB-IRIS
lymph node involvement, TB-IRIS pulmonary involve-
ment, drug-resistant TB, as well as age, gender and hos-
pitalisation. TB-IRIS lymph node involvement was
statistically significantly associated with a lower hazard
of TB-IRIS resolution (HR 0.55, 95 % CI 0.38–0.78; p =
0.0009) in both the full model and the model run with-
out Cohort 2 (HR 0.60, 95 % CI 0.40–0.89; p = 0.01,
Table 6). In a sensitivity analysis, the Cox proportional
hazards model including patients from all three cohorts
was re-run excluding patients with rifampicin resistance
(n = 18) and excluding drug-resistance as a co-variate.
TB-IRIS lymph node involvement remained significantly
associated with outcome (data not shown). Additionally,
a competing risks model was developed to account
for the competing risks of death and IRIS resolution
and the model for IRIS resolution demonstrated simi-
lar findings to that of the Cox proportional hazards
model (Additional file 3: Table S2). In Fig. 2, the
Kaplan-Meier plot demonstrates more rapid TB-IRIS
resolution for those without lymph node TB-IRIS
compared to those with TB-IRIS with lymph node in-
volvement (p < 0.0001; log-rank test).
Discussion
In this combined analysis that included patients enrolled
in three previously reported studies the duration of para-
doxical TB-IRIS symptoms was a median of 71 days
(IQR 41–113), with 40.3 % of patients experiencing TB-
IRIS symptoms lasting > 90 days. Six patients (3.3 %)
experienced a very protracted course of TB-IRIS with
symptoms > 1 year duration. TB-IRIS lymph node in-
volvement was independently associated with a longer
duration of symptoms.
Table 4 Odds ratios for univariate (unadjusted) and multivariate (adjusted) logistic regression models predicting the development of
prolonged TB-IRIS (n = 181)
Unadjusted OR (95 % CI) Unadjusted p-value Adjusted OR (95 % CI) Adjusted p-value
Age (per 1 year increase) 0.97 (0.93–1.01) 0.16 0.98 (0.94–1.05) 0.48
Male gender 0.72 (0.38–1.35) 0.31 0.80 (0.39–1.63) 0.54
Lymph node involvement at initial TB diagnosis 2.36 (1.18–4.76) 0.02 1.79 (0.81–3.98) 0.15
Drug-resistant TBa 4.13 (1.32–15.56) 0.02 3.26 (0.97–12.99) 0.07
Hospitalised at time of TB-IRIS diagnosis 0.40 (0.22–0.75) 0.004 0.5 (0.25–0.99) 0.05
TB-IRIS lymph node involvement 3.01 (1.63–5.65) 0.0005 2.27 (1.13–4.59) 0.02
TB-IRIS pulmonary involvement 0.54 (0.29–1.02) 0.06 0.65 (0.32–1.30) 0.23
Cohort 2b 0.06 (0.01–0.18) < 0.0001 Not included
Cohort 1b 0.29 (0.12–0.62) 0.002 Not included
Abbreviations: IRIS immune reconstitution inflammatory syndrome, TB tuberculosis
aThe reference group is combined culture negative, culture not done and drug susceptible
bReference cohort was randomized controlled trial
Table 5 Cox proportional hazards model predicting time to
resolution of TB-IRIS symptoms
Adjusted HR (95 % CI) p-value
Age (per 1 year increase) 0.99 (0.97–1.01) 0.51
Male gender 1.22 (0.86–1.74) 0.27
Lymph node involvement at initial
TB diagnosis
0.75 (0.50–1.15) 0.19
Drug-resistant TB 0.60 (0.34–1.08) 0.09
Hospitalised at time of TB-IRIS diagnosis 1.28 (0.92–1.78) 0.14
TB-IRIS pulmonary involvement 1.29 (0.92–1.81) 0.14
TB-IRIS lymph node involvement 0.55 (0.38–0.78) 0.0009
Abbreviations: IRIS immune reconstitution inflammatory syndrome,
TB tuberculosis
Table 6 Cox proportional hazards model predicting time to
resolution of TB-IRIS symptoms excluding Brooklyn Chest Hospital
cohort (Cohort 2)
Adjusted HR (95 % CI) p-value
Age (per 1 year increase) 0.99 (0.96–1.01) 0.36
Male gender 1.42 (0.92–2.18) 0.11
Lymph node involvement at initial
TB diagnosis
0.72 (0.44–1.17) 0.18
Drug-resistant TB 0.65 (0.36–1.20) 0.17
Hospitalised at time of TB-IRIS diagnosis 0.93 (0.62–1.40) 0.73
TB-IRIS pulmonary involvement 1.23 (0.82–1.83) 0.32
TB-IRIS lymph node involvement 0.60 (0.40–0.89) 0.01
In the Cox proportional hazards model, even when the Brooklyn Chest
Hospital cohort (Cohort 2) was excluded, TB-IRIS lymph node involvement
remained statistically significantly associated with a lower hazard of TB-IRIS
resolution (aHR 0.60, 95 % CI 0.40–0.89; p = 0.01)
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The TB-IRIS case fatality rate in the combined cohort
was 7.4 %, with 5 of the 16 deaths attributed to TB-IRIS.
This is similar to the all-cause mortality rate reported in
a recent TB-IRIS meta-analysis (7 %) [4], but lower than
that reported in certain studies. In the CAMELIA trial
mortality amongst the 155 TB-IRIS cases was higher
than in our study (23 deaths among the 155 patients
(14.8 %) with 6 deaths attributed to TB-IRIS), likely a
consequence of the advanced immunosuppression at
ART initiation in the CAMELIA participants (median
CD4 = 27 cells/μl) [7].
Hospitalisation at TB-IRIS diagnosis was associated
with IRIS duration ≤ 90 days (aOR 0.5, 95 % CI 0.25–
0.99; p = 0.05). One possible explanation for these find-
ings is that in Cohort 2 (study conducted at Brooklyn
Chest TB Hospital) all patients were in hospital at time
of ART initiation and there was close prospective follow
up during early ART, TB-IRIS was likely diagnosed early
and treated promptly with corticosteroids when needed
thereby potentially reducing duration. This close follow-
up may also have resulted in diagnosis of milder cases of
inherently shorter duration. When Cohort 2 was ex-
cluded from a sensitivity analysis the association of
prolonged TB-IRIS duration with hospitalisation was no
longer observed.
Abdominal manifestations were the most frequent
IRIS clinical feature in our study, which has not been
reported in previous studies [4]. This was in part
related to the permissive definition we used for ab-
dominal IRIS which included any patient who had
TB-IRIS fulfilling INSHI criteria and who in addition
had an abdominal symptom attributed to TB-IRIS,
hepatomegaly on clinical examination or abdominal
ultrasound features of TB at the time of TB-IRIS. In
a previous report, that included patients in this study,
we reported over 50 % of TB-IRIS patients had hep-
atomegaly and many had cholestatic liver function
derangement at TB-IRIS presentation [13].
In the 6 patients who had TB-IRIS lasting > 1 year the
prolonged features were nodal enlargement and nodal
suppuration as well as abscess formation, including
cerebellar abscesses in one case. These patients received
prolonged corticosteroids and four had one or more
relapses when steroids were tapered or interrupted.
However, in all of them corticosteroids were eventually
stopped long before IRIS resolution because of the
clinical impression that they were no longer providing
benefit and concerns regarding cumulative toxicity. The
longest duration of corticosteroid therapy was 308 days,
and the longest duration of TB-IRIS was almost 4 years.
Fig. 2 Kaplan-Meier plot showing time to TB-IRIS resolution. The graph shows the comparison of time to TB-IRIS resolution between patients
who had TB-IRIS lymph node involvement to those patients who did not. Resolution was more rapid in those without lymph node involvement
(p < 0.0001, log-rank test)
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Prolonged IRIS represents a key management challenge
in ART programmes. Prolonged IRIS has best been de-
scribed in patients with Mycobacterium avium complex
(MAC) and other non-tuberculous mycobacterial (NTM)
infections. Phillips [17] reported 51 patients with NTM
IRIS in whom the median duration of IRIS symptoms was
6 months with a range of 0–27 months. Riddell [18] re-
ported the long-term outcomes of MAC-IRIS for 20 pa-
tients: 16 responded to treatment and were disease free
after a mean of 17.4 months of therapy for MAC-IRIS,
whereas four patients had persistent or relapsing disease
despite 27 months of treatment. For paradoxical TB-IRIS
several studies have reported on the duration of symptoms
and cases with a prolonged course have previously been
described. The median duration of TB-IRIS symptoms re-
ported across studies has been between 40 and 90 days
[5–9, 11]. In the SAPiT trial those patients who started
ART within 4 weeks of TB treatment and developed TB-
IRIS had a significantly longer duration of TB-IRIS (me-
dian 71 days) compared to TB-IRIS cases who started
ART 8–12 weeks after TB treatment (median 34 days)
[10]. In the CAMELIA trial, 155 cases of TB-IRIS were
diagnosed, 77 % with nodal involvement and 38 % were
treated with corticosteroids and 36 % with non-steroidal
anti-inflammatory drugs. The median duration of IRIS
was 7.4 weeks (IQR 4–19.8) [7]. Ollala et al. [11] reported
a very variable duration of mycobacterial IRIS (between
19 days and more than 395 days, median of 57 days), and
duration was longer in those patients whose paradoxical
responses manifested the appearance or increase in
lymphadenopathy (median 195 days) similar to our study.
Huyst et al. [19] reported a case with two episodes of IRIS
associated with TB; the first episode occurring soon after
initiation of ART and the second episode occurring almost
4 years later. Similar to our findings, Burman et al. re-
ported 10/25 (40 %) patients with TB-IRIS with a dur-
ation > 90 days. In two patients the duration of TB-IRIS
was > 1 year and one required 108 aspirations of the IRIS
lymph nodes [5]. Breton et al. reported four among 34 pa-
tients who had long term relapses lasting 14 months,
20 months, 3 and 4 years [12]. Naidoo et al. reported two
cases of TB-IRIS unresolved after 18 months of trial
follow-up in the SAPiT trial [10] and Michailidis et al. a
case with a discharging psoas abscess for 15 months [9].
The risk factors most consistently implicated in the
development of TB-IRIS are a low pre-ART CD4 count,
short duration between starting TB treatment and ART,
and extra-pulmonary TB [20]. Neither of the first two
was found to be associated with prolonged TB-IRIS
whereas TB-IRIS lymph node involvement (an extra-
pulmonary manifestation) was, suggesting there is a
common risk factor for developing TB-IRIS itself and
for a prolonged course of TB-IRIS. In the CAMELIA
trial mediastinal adenopathy was a risk factor for TB-
IRIS [7] and in a Brazilian observational study superficial
adenopathy was a TB-IRIS risk factor [21]. Nodal TB is
also associated with a high incidence of paradoxical re-
actions in HIV-negative TB patients [22]. Multiple lines
of evidence therefore suggest TB in a nodal location in-
creases the risk for inflammatory reactions and in our
study and the Ollala et al. study [11] a longer duration
of these inflammatory reactions. In a recently published
study Lerner et al. identified lymphatic endothelial cells
(LECs), which line the lymphatic vessels in lymph nodes,
as a niche for Mycobacterium tuberculosis replication.
They suggest that these cells could represent an
immune-privileged site [23]. The resultant abundant
replication of Mycobacterium tuberculosis in these cells
could result in high amounts of antigen in lymph nodes
that become a stimulus for prolonged TB-IRIS.
A limitation of this study is that it included patients en-
rolled in three separate studies introducing heterogeneity.
One of the studies was an RCT, and two were observa-
tional studies. The RCT and one of the observational stud-
ies (Cohort 1) were conducted at a referral hospital and
the other observational study (Cohort 2) at an inpatient
TB hospital. This weakness was mitigated by the use of
the same diagnostic approach and case definition for TB-
IRIS across the three studies. Also, the studies were all
conducted by the same research group. Management pro-
tocols for TB-IRIS (apart from during the intervention
period of the RCT) were similar across studies. Given that
two of the studies were conducted at a referral hospital,
this may have excluded milder cases of TB-IRIS who were
not referred from primary care, biasing the findings
towards patients with more severe TB-IRIS who may
be more likely to die or have prolonged TB-IRIS. The
location of the studies also affected the loss to follow-
up reported: loss to follow-up was defined as loss to
follow-up at the referral or TB hospital and did not ne-
cessarily mean the patient was also lost to follow-up at
their primary care HIV or TB clinic. In the analyses we
included multiple variables and no correction for mul-
tiple comparisons was conducted. Consistent with
INSHI case definitions, the definitions of lymph node
TB-IRIS and abdominal TB-IRIS were not mutually ex-
clusive (ie. a patient with symptomatic enlarging ab-
dominal lymphadenopathy was classified as having
both nodal and abdominal TB-IRIS). Data relating to
time of TB-IRIS onset relied on patient history which
might have been subjective and prone to recall bias.
A strength of this study is the large number of patients
with paradoxical TB-IRIS included. This is to our know-
ledge the largest number of TB-IRIS patients to be in-
cluded in a single analysis, and this allowed us to
present important and novel findings with respect to the
clinical course of TB-IRIS and the contributing factors.
All patients fulfilled the INSHI case definition, apart
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from the inclusion of certain patients with drug resistant
TB who were also considered to have TB–IRIS.
Conclusions
Around 40 % of patients with TB-IRIS have a clinical
course of symptoms lasting longer than 90 days. Lymph
node IRIS involvement is an independent risk factor for
a prolonged course. In the small proportion of patients
(3 %) with symptoms lasting more than 1 year this mani-
fests with lymphadenitis and abscess formation. Whether
earlier recognition and treatment of lymph node TB-
IRIS could reduce the risk for prolonged TB-IRIS needs
to be evaluated in future studies.
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